Like rapamycin, Akt inhibitors, notably Akt-inhibitor VIII and GDC-0068, enhanced the expansion of tumor-specific lymphocytes and promoted the ex vivo generation of stem cell memory-like CD8+ T cells (CD62Lhigh CCR7high CXCR4high) with a unique metabolic profile and cytokine polyfunctionality (26–29). Here, AKT1 is linked to neoplasm.